Slika omota

Estimating the effectiveness of remdesivir on risk of COVID-19 mortality: The role of observational data

Spremljeno u:

Bibliografski detalji
Glavni autori:	Andrea Giacomelli (Autor), Alessandro Cozzi-Lepri (Autor), Giacomo Casalini (Autor), Letizia Oreni (Autor), Anna Lisa Ridolfo (Autor), Spinello Antinori (Autor)
Format:	Knjiga
Izdano:	Elsevier, 2022-07-01T00:00:00Z.
Teme:	article
Online pristup:	Connect to this object online.
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Bloodstream Infections in Intensive Care Unit during Four Consecutive SARS-CoV-2 Pandemic Waves
od: Giacomo Pozza, i dr.
Izdano: (2023)

Impact of a Bundle of Interventions on Quality-of-Care Indicators for <i>Staphylococcus aureus</i> Bacteraemia: A Single-Centre, Quasi-Experimental, Before-After Study
od: Giacomo Casalini, i dr.
Izdano: (2024)

Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy
od: Laura Milazzo, i dr.
Izdano: (2021)

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects
od: Giacomelli A, i dr.
Izdano: (2019)

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
od: Aksak-Wąs BJ, i dr.
Izdano: (2022)

Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study
od: Abigail Schulz, i dr.
Izdano: (2024)

Inequalities in child mortality: real data or modelled estimates?
od: Cesar G Victora, i dr.
Izdano: (2018)

The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis
od: Chenchula Santenna, i dr.
Izdano: (2021)

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19
od: Alireza FakhriRavari, i dr.
Izdano: (2024)

Postmarketing pharmacovigilance: Remdesivir and cardiovascular events
od: John T. Sullivan
Izdano: (2022)

Chitosan-Based Nanocarriers for Delivery of Remdesivir
od: Viktoria Milkova, i dr.
Izdano: (2023)

The journey of remdesivir: from Ebola to COVID-19
od: Joe Pardo, i dr.
Izdano: (2020)

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys
od: Lin Xu, i dr.
Izdano: (2021)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
od: Alexandra A. Taube, i dr.
Izdano: (2020)

Remdesivir-Bringing Hope for COVID-19 Treatment
od: Naser F. Al-Tannak, i dr.
Izdano: (2020)

Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions
od: Subrata Deb, i dr.
Izdano: (2021)

The use of Remdesivir in pregnant women with COVID-19
od: Gulbanu Shaimerdenova, i dr.
Izdano: (2023)

Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review
od: Catherine Smith, i dr.
Izdano: (2024)

Estimating national excess mortality from subnational data: application to Argentina
od: Ariel Karlinsky
Izdano: (2022)

Estimates of pandemic excess mortality in India based on civil registration data.
od: Murad Banaji, i dr.
Izdano: (2022)

Estimates of pandemic excess mortality in India based on civil registration data
od: Murad Banaji, i dr.
Izdano: (2022)

Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic
od: Dario Cattaneo, i dr.
Izdano: (2023)

Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic
od: Mariacristina Poliseno, i dr.
Izdano: (2021)

Estimating cause-specific mortality from community- and facility-based data sources in the United Republic of Tanzania: options and implications for mortality burden estimates
od: David R Whiting, i dr.
Izdano: (2006)

Treatment of patients hospitalized for COVID-19 with remdesivir is associated with lower likelihood of 30-day readmission: a retrospective observational study
od: Essy Mozaffari, i dr.
Izdano: (2024)

The impact of an antimicrobial stewardship program restriction on remdesivir prescribing
od: Kristen E. Zeitler, i dr.
Izdano: (2022)

Protective Effect of Remdesivir Against Pulmonary Fibrosis in Mice
od: Xiaohe Li, i dr.
Izdano: (2021)

Análisis epidemiológico de pacientes tratados con Remdesivir
od: Víctor Fernández Martínez
Izdano: (2022)

Análisis epidemiológico de pacientes tratados con Remdesivir
od: Víctor Fernández Martínez
Izdano: (2022)

Experience of Using Remdesivir in Patients with Novel Coronavirus Infection
od: V. I. Petrov, i dr.
Izdano: (2022)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
od: Rita Humeniuk, i dr.
Izdano: (2023)

Current and future use of remdesivir in patients with COVID-19
od: V. M. Tsvetov, i dr.
Izdano: (2020)

Remdesivir in a pregnant patient with COVID-19 pneumonia
od: Ranadheer Dande, i dr.
Izdano: (2021)

Estimating pregnancy-related mortality from census data: experience in Latin America
od: Kenneth Hill, i dr.
Izdano: (2009)

Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources
od: Borgia Piero, i dr.
Izdano: (2011)

Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
od: Moreno S, i dr.
Izdano: (2022)

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study
od: Yu. V. Shevchuk, i dr.
Izdano: (2023)

Use of Remdesivir in children with COVID-19: report of an Italian multicenter study
od: Lorenza Romani, i dr.
Izdano: (2024)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
od: Dimple Patel, i dr.
Izdano: (2023)

Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
od: Flor álvarez de Toledo
Izdano: (2020)